Read this topic

Antipsychotics are drugs used to treat psychosis (a mental state where a person loses touch with reality, with symptoms such as hallucinations or delusions). All antipsychotics share one core action: they block D2 receptors, the main docking site for dopamine (a brain chemical, or neurotransmitter, involved in reward, motivation, and movement) in several brain pathways. What separates an older, first-generation typical antipsychotic like haloperidol from a newer, second-generation atypical antipsychotic like risperidone or olanzapine is not just how strongly it blocks D2 receptors, but which OTHER receptors it also blocks, and in what balance. For example, imagine two antipsychotics with identical dopamine-blocking strength at the D2 receptor: if one of them ALSO blocks a serotonin receptor called 5-HT2A, that drug causes noticeably less stiffness and tremor than the one that blocks D2 alone. This receptor ratio, not the raw dose, is one of the most heavily tested ideas in psychopharmacology (the study of how drugs affect the mind and behaviour).

"Atypical" does not mean "newer" or "gentler" as a blanket description: it refers to a specific pharmacological difference from typical antipsychotics: a broader or different receptor-binding pattern beyond pure D2 blockade. Every antipsychotic, typical or atypical, treats psychosis through D2 blockade in the same core pathway. What makes a drug atypical is an additional mechanism: extra serotonin blockade, low overall D2 occupancy, or D2 partial agonism, that changes its side-effect profile without abandoning the D2 blockade that makes it work.

The trap most students fall into is assuming that "atypical" simply means "blocks dopamine more gently." It doesn't. Two drugs can block D2 receptors with equal strength and still behave completely differently, because what determines the side-effect profile is the BALANCE between D2 blockade and other receptor actions, not the absolute strength of D2 blockade alone. A drug with strong D2 blockade plus strong 5-HT2A blockade can still spare movement pathways, while a drug with only moderate D2 blockade and no other receptor action can still cause significant stiffness. Judging a drug purely by "how strong is the dopamine block" misses the mechanism the exam is actually testing.

Dopamine runs through four separate pathways in the brain, and antipsychotics affect all of them at once, which is why one drug can help psychosis while also causing side effects elsewhere. The mesolimbic pathway is where excess dopamine activity is thought to drive positive psychotic symptoms (hallucinations and delusions), so D2 blockade here is the treatment target. The nigrostriatal pathway controls movement; blocking D2 receptors here causes extrapyramidal side effects (EPS, drug-induced movement problems such as rigidity, tremor, and restlessness). The tuberoinfundibular pathway normally uses dopamine to suppress prolactin (a hormone that stimulates milk production); blocking D2 receptors here raises prolactin, which can cause breast enlargement, missed periods, or reduced libido. The mesocortical pathway is linked to negative symptoms and cognition. Atypical antipsychotics achieve a high ratio of 5-HT2A blockade relative to D2 blockade; blocking 5-HT2A receptors disinhibits (releases the brake on) dopamine release specifically in the nigrostriatal pathway, partially offsetting the D2 blockade there and protecting movement, while the antipsychotic effect is preserved because D2 blockade continues unopposed in the mesolimbic pathway. A related idea, the "fast-off D2" theory, describes some atypicals binding D2 receptors loosely and dissociating (releasing) from them quickly, giving a similar side-effect-sparing effect without needing much 5-HT2A involvement at all.

Clozapine is the prototype atypical antipsychotic and sits at one extreme of the receptor spectrum. It has low D2 receptor occupancy, meaning it does not block a large fraction of D2 receptors even at effective doses, and instead binds broadly across many receptor types, including 5-HT2A, muscarinic, histaminic, and alpha-adrenergic receptors. This broad, low-D2-occupancy binding profile explains clozapine's very low EPS risk, but also its wide range of other side effects, such as sedation, weight gain, hypersalivation, and constipation. Quetiapine behaves similarly: it also has relatively low D2 occupancy at standard doses, which is why quetiapine, like clozapine, carries low EPS risk. Aripiprazole works through an entirely different mechanism: rather than blocking D2 receptors outright, it is a D2 partial agonist, meaning it activates the D2 receptor but only weakly compared with dopamine's full activation. In a brain region with too much dopamine activity (as in mesolimbic psychosis), aripiprazole acts as a relative antagonist, dampening excess signalling; in a region with too little dopamine activity, it acts as a relative agonist, propping signalling up. This dopamine-stabilising action, rather than a specific 5-HT2A:D2 ratio, is why aripiprazole also causes comparatively low EPS and low prolactin elevation. Risperidone and olanzapine represent the "classic" atypical route: strong D2 blockade balanced by a high ratio of 5-HT2A blockade, sparing movement pathways while still treating psychosis.

The three atypical mechanisms produce distinguishable side-effect signatures, and confusing them is a common exam trap. Low-D2-occupancy drugs (clozapine, quetiapine) cause sedation, weight gain, and hypersalivation, with minimal rigidity or prolactin rise. High-5-HT2A:D2-ratio drugs (risperidone, olanzapine) cause less EPS than a typical antipsychotic but can still raise prolactin, especially risperidone, because its D2 blockade remains relatively strong. Partial-agonist drugs (aripiprazole) cause low EPS and low prolactin elevation but a distinctive side effect of their own: akathisia (a subjective inner restlessness, an urge to keep moving) that is easily mistaken for anxiety or worsening agitation rather than a medication side effect. It is also worth separating acute EPS (rigidity, tremor, dystonia appearing within days) from tardive dyskinesia (involuntary, often orofacial movements that emerge after months to years of treatment and may persist even after the drug is stopped), both stem from dopamine pathway disruption, but their timing and reversibility differ completely.

There is no single test for "which receptor profile is causing this." Diagnosis is clinical, built from examination and targeted blood tests read alongside the medication history. EPS is diagnosed at the bedside: cog-wheel or lead-pipe rigidity felt when a doctor moves the patient's limb, a resting tremor, or dystonia (sustained muscle contraction). Hyperprolactinaemia is confirmed with a prolactin blood test when a patient reports breast changes, menstrual disturbance, or reduced libido on a high-D2-occupancy drug. Before and during clozapine treatment specifically, regular full blood count monitoring is mandatory, screening for agranulocytosis (a dangerously low white blood cell count): this is the one receptor-profile-related investigation with a fixed, guideline-mandated schedule rather than being triggered by symptoms.

Consider a patient established on a typical antipsychotic who develops troublesome rigidity and tremor. A clinician recognises this as EPS from high D2 occupancy in the nigrostriatal pathway, and first-line management is switching to an atypical antipsychotic with a high 5-HT2A:D2 ratio, such as risperidone at a low-to-moderate dose, which typically improves the stiffness because the added serotonin blockade spares the movement pathway while dopamine blockade continues treating the psychosis in the mesolimbic pathway. If the patient's psychosis has proven resistant to two adequate trials of other antipsychotics, both NICE and the Maudsley Prescribing Guidelines recommend a trial of clozapine as the evidence-based next step, since clozapine has proven, effective management for treatment-resistant schizophrenia despite needing regular blood monitoring for agranulocytosis. Where akathisia rather than psychotic agitation is suspected on aripiprazole, management is dose reduction or switching, not increasing the antipsychotic dose: mistaking akathisia for worsening psychosis and raising the dose only makes the restlessness worse.

A candidate should be able to look at a drug's clinical side-effect pattern and infer the likely receptor mechanism without needing to recall a table. High prolactin plus significant rigidity points to a high-D2-occupancy drug. Sedation, weight gain, and hypersalivation with minimal rigidity points toward clozapine or quetiapine's low-D2-occupancy, broad-binding profile. A patient who is restless and pacing but denies feeling anxious, on aripiprazole, with neither strong EPS nor strong prolactin elevation, points toward partial-agonist akathisia rather than agitation, and the correct answer is to address the drug, not to sedate the "agitation."

It is the BALANCE between D2 blockade and other receptor actions: extra 5-HT2A blockade, low overall D2 occupancy, or D2 partial agonism, not the raw strength of dopamine blockade, that determines whether an antipsychotic causes movement side effects and prolactin elevation.